Hepatologia

Spatial single-cell omics: new insights into liver diseases.

Gut. 2026 May; 75(May):1248-1263. doi: 10.1136/gutjnl-2024-332105. pii: e332105.

AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2026 May; 58(May):599-607. doi: 10.1016/j.dld.2026.02.014. pii: S1590-8658(26)00292-6.

International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment.

The Lancet. Oncology. 2026 May; 27(May):e248-e258. doi: 10.1016/S1470-2045(26)00143-9. pii: S1470-2045(26)00143-9.

International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards.

The Lancet. Oncology. 2026 May; 27(May):e259-e270. doi: 10.1016/S1470-2045(26)00114-2. pii: S1470-2045(26)00114-2.

Inpatient Management of Patients With Cirrhosis.

Annals of internal medicine. 2026 Apr; 179(Apr):ITC49-ITC64. doi: 10.7326/ANNALS-26-00513. pii: .

Navigating Complexities in the Liver Intensive Care Unit: Bridging Critical Care and Hepatology.

The American journal of gastroenterology. 2026 Jan; doi: 10.14309/ajg.0000000000003900. pii: .

Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment.

American journal of hematology. 2026 May; 101(May):1056-1069. doi: 10.1002/ajh.70246. pii: .

Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management.

Nature reviews. Gastroenterology & hepatology. 2026 May; 23(May):411-431. doi: 10.1038/s41575-025-01159-4. pii: .

Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease.

Nature reviews. Gastroenterology & hepatology. 2026 May; 23(May):395-410. doi: 10.1038/s41575-025-01168-3. pii: .

Neutrophil extracellular traps: A central player in liver diseases.

Hepatology communications. 2026 Jun; 10(Jun):doi: 10.1097/HC9.0000000000000970. pii: e0970.

Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.

Hepatology (Baltimore, Md.). 2026 May; 83(May):1326-1340. doi: 10.1097/HEP.0000000000001608. pii: .

Variceal hemorrhage in cirrhosis.

Expert review of gastroenterology & hepatology. 2026 May; 20(May):439-447. doi: 10.1080/17474124.2026.2656231. pii: .

Transplant hepatology: New epidemiology and indications.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2026 May; 58(May):591-598. doi: 10.1016/j.dld.2026.01.231. pii: S1590-8658(26)00265-3.

Regression of fibrosis and portal hypertension in chronic liver disease: Endothelial perspectives and clinical implications.

Annals of hepatology. 2026 ; 31():102174. doi: 10.1016/j.aohep.2025.102174. pii: S1665-2681(25)00399-0.

Management of Refractory Hepatic Encephalopathy.

Digestive diseases and sciences. 2026 May; 71(May):1686-1693. doi: 10.1007/s10620-025-09591-x. pii: .

Plasma exchange in acute liver failure.

Current opinion in gastroenterology. 2026 May; 42(May):129-135. doi: 10.1097/MOG.0000000000001166. pii: .

Precision medicine in steatotic liver disease.

Current opinion in gastroenterology. 2026 May; 42(May):121-128. doi: 10.1097/MOG.0000000000001165. pii: .

The utility of albumin in cirrhosis: established benefits and unanswered questions.

Current opinion in gastroenterology. 2026 May; 42(May):114-120. doi: 10.1097/MOG.0000000000001155. pii: .

The alcohol-associated hepatitis treatment landscape.

Current opinion in gastroenterology. 2026 May; 42(May):107-113. doi: 10.1097/MOG.0000000000001158. pii: .

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease. 2026 May; 30(May):557-569. doi: 10.1016/j.cld.2026.01.013. pii: S1089-3261(26)00013-9.

What's New in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis.

Clinics in liver disease. 2026 May; 30(May):469-481. doi: 10.1016/j.cld.2026.01.008. pii: S1089-3261(26)00008-5.

Special Population: A Global Perspective on Metabolic Dysfunction-Associated Alcohol-Related Liver Disease.

Clinics in liver disease. 2026 May; 30(May):449-467. doi: 10.1016/j.cld.2026.01.007. pii: S1089-3261(26)00007-3.

Special Population: Lean MASH.

Clinics in liver disease. 2026 May; 30(May):435-447. doi: 10.1016/j.cld.2026.01.006. pii: S1089-3261(26)00006-1.

Special Populations: Hepatocellular Carcinoma Risk and Liver Transplantation.

Clinics in liver disease. 2026 May; 30(May):417-433. doi: 10.1016/j.cld.2026.01.005. pii: S1089-3261(26)00005-X.

Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.

Clinics in liver disease. 2026 May; 30(May):391-415. doi: 10.1016/j.cld.2026.01.004. pii: S1089-3261(26)00004-8.

Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes.

Clinics in liver disease. 2026 May; 30(May):381-390. doi: 10.1016/j.cld.2026.01.003. pii: S1089-3261(26)00003-6.

Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification.

Clinics in liver disease. 2026 May; 30(May):359-379. doi: 10.1016/j.cld.2026.01.002. pii: S1089-3261(26)00002-4.

Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis.

Clinics in liver disease. 2026 May; 30(May):343-358. doi: 10.1016/j.cld.2025.12.005. pii: S1089-3261(25)00107-2.

Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.

Clinics in liver disease. 2026 May; 30(May):323-342. doi: 10.1016/j.cld.2025.12.004. pii: S1089-3261(25)00106-0.

AASLD AST Practice Guideline on adult liver transplantation: Diagnosis and management of graft-related complications.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2026 Mar; 32(Mar):444-490. doi: 10.1097/LVT.0000000000000715. pii: .

Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials.

Journal of hepatology. 2026 Apr; 84(Apr):693-701. doi: 10.1016/j.jhep.2025.09.019. pii: S0168-8278(25)02501-2.

An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2026 Mar; 24(Mar):633-645.e4. doi: 10.1016/j.cgh.2025.02.017. pii: S1542-3565(25)00325-8.

British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis.

Gut. 2025 Aug; 74(Aug):1364-1409. doi: 10.1136/gutjnl-2024-333171. pii: e333171.

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.

Journal of hepatology. 2025 Feb; 82(Feb):315-374. doi: 10.1016/j.jhep.2024.08.028. pii: S0168-8278(24)02508-X.

The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2025 Jun; 31(Jun):815-831. doi: 10.1097/LVT.0000000000000589. pii: .

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

Hepatology (Baltimore, Md.). 2023 Dec; 78(Dec):1922-1965. doi: 10.1097/HEP.0000000000000466. pii: .

A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

Journal of hepatology. 2023 Jun; doi: 10.1016/j.jhep.2023.06.003. pii: S0168-8278(23)00418-X.

EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.

Journal of hepatology. 2023 Jul; 79(Jul):181-208. doi: 10.1016/j.jhep.2023.03.010. pii: S0168-8278(23)00185-X.

EASL Clinical Practice Guidelines on hepatitis delta virus.

Journal of hepatology. 2023 Aug; 79(Aug):433-460. doi: 10.1016/j.jhep.2023.05.001. pii: S0168-8278(23)00317-3.

EASL Clinical Practice Guidelines on acute-on-chronic liver failure.

Journal of hepatology. 2023 Aug; 79(Aug):461-491. doi: 10.1016/j.jhep.2023.04.021. pii: S0168-8278(23)00244-1.

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.

Journal of hepatology. 2023 Nov; 79(Nov):1254-1269. doi: 10.1016/j.jhep.2023.06.002. pii: S0168-8278(23)00417-8.

ACG Clinical Guideline: Focal Liver Lesions.

The American journal of gastroenterology. 2024 Jul; 119(Jul):1235-1271. doi: 10.14309/ajg.0000000000002857. pii: .

Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy.

Drug safety. 2024 Apr; 47(Apr):321-332. doi: 10.1007/s40264-024-01399-4. pii: .

AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.

Gastroenterology. 2024 Jan; 166(Jan):202-210. doi: 10.1053/j.gastro.2023.10.016. pii: S0016-5085(23)05143-0.

AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.

Gastroenterology. 2023 Oct; 165(Oct):1080-1088. doi: 10.1053/j.gastro.2023.06.013. pii: S0016-5085(23)00881-8.

Hepatitis B: A Review.

JAMA. 2026 Jun; 335(Jun):1879-1892. doi: 10.1001/jama.2026.6070. pii: .

Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management.

The lancet. Gastroenterology & hepatology. 2026 Jun; 11(Jun):521-537. doi: 10.1016/S2468-1253(25)00323-1. pii: S2468-1253(25)00323-1.

Neutrophil extracellular traps: A central player in liver diseases.

Hepatology communications. 2026 Jun; 10(Jun):doi: 10.1097/HC9.0000000000000970. pii: e0970.

Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE Score.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2026 May; doi: 10.1016/j.cgh.2026.04.033. pii: S1542-3565(26)00389-7.

Spatial single-cell omics: new insights into liver diseases.

Gut. 2026 May; 75(May):1248-1263. doi: 10.1136/gutjnl-2024-332105. pii: e332105.

Variceal hemorrhage in cirrhosis.

Expert review of gastroenterology & hepatology. 2026 May; 20(May):439-447. doi: 10.1080/17474124.2026.2656231. pii: .

Transplant hepatology: New epidemiology and indications.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2026 May; 58(May):591-598. doi: 10.1016/j.dld.2026.01.231. pii: S1590-8658(26)00265-3.

Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases.

Clinics in liver disease. 2026 May; 30(May):301-322. doi: 10.1016/j.cld.2025.12.003. pii: S1089-3261(25)00105-9.

Precision medicine in steatotic liver disease.

Current opinion in gastroenterology. 2026 May; 42(May):121-128. doi: 10.1097/MOG.0000000000001165. pii: .

Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes.

Clinics in liver disease. 2026 May; 30(May):381-390. doi: 10.1016/j.cld.2026.01.003. pii: S1089-3261(26)00003-6.